The GLP

Why GLP-1 drugs like semaglutide and tirzepatide faced years of shortages , how manufacturing is catching up, and what the compounding fallout means now.

Although the shortages ended in early 2025, some compounding facilities may still be compounding large quantities of GLP-1 drugs . This study will assess FDA's efforts to oversee the compounding of GLP-1 drugs , including the extent to which FDA inspects compounders and leverages available data to identify and address potential risks.
Key Details About Glp 1 Drug Shortages And Compounding

The GLP-1 shortage was a collision between unprecedented demand and the physical limits of peptide manufacturing. It lasted nearly three years, affected millions of patients, spawned a compounding industry that is now being dismantled by regulation, and prompted tens of billions of dollars in manufacturing investment.
What Is Compounded GLP-1 and Why Did the FDA Get Involved? Compounded GLP-1 medications are custom-made versions of drugs like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), prepared by licensed compounding pharmacies. They became popular during the 2022-2024 shortage period because they were significantly cheaper than branded versions — often $150-$300/month versus ...

FDA Moves to Permanently Close the Door on Compounded GLP
Key Takeaways Proposed rule would bar 503B outsourcing facilities from bulk compounding of these glucagon-like peptide-1 receptor agonists, removing bulks-list and shortage -list pathways for semaglutide, tirzepatide, and liraglutide. Demand-driven shortages beginning in 2022 enabled widespread compounding at approximately $150 to $300 per month vs more than $1000 branded pricing, until the FDA ...
The GLP-1 compounding ban is, at its core, a collision between drug pricing, patent law, pharmaceutical regulation, and patient access. Compounding pharmacies provided affordable GLP-1 medications to millions of people during a genuine shortage .

FDA GLP
Quick Answer: Is the GLP-1 shortage over in 2026? Mostly yes, but with caveats. The FDA officially removed semaglutide (Wegovy/Ozempic) from the drug shortage list in early 2025. Tirzepatide (Zepbound/Mounjaro) supply has also largely resolved. Brand pens are stocked at most US retail pharmacies as of May 2026. What this means for compounded GLP-1 : compounding is still legal and active under ...
For consumers unwilling or unable to pay for GLP-1 medications like Ozempic, Wegovy and Zepbound, the offers from compounding pharmacies — rather than mainstream manufacturers of the drugs — are appealing. Indeed, at their peak in 2024, nearly 1 in 3 Americans taking a GLP-1 drug said they were getting it from a compounding pharmacy.

FDA clarifies policies for compounders as national GLP
The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 ( GLP-1 ) medication, has been resolved.







Last week, FDA declared that GLP-1 drugs for diabetes and weight loss are no longer in shortage — a decision that could have widespread impacts on companies offering compounded versions of the drugs . Here's what you need to know.